Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
N Engl J Med. Author manuscript; available in PMC 2011 May 3.
Published in final edited form as:
PMCID: PMC3086629

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

Alice L. Yu, M.D., Ph.D., Andrew L. Gilman, M.D., M. Fevzi Ozkaynak, M.D., Wendy B. London, Ph.D., Susan G. Kreissman, M.D., Helen X. Chen, M.D., Malcolm Smith, M.D., Ph.D., Barry Anderson, M.D., Judith G. Villablanca, M.D., Katherine K. Matthay, M.D., Hiro Shimada, M.D., Stephan A. Grupp, M.D., Ph.D., Robert Seeger, M.D., C. Patrick Reynolds, M.D., Ph.D., Allen Buxton, M.S., Ralph A. Reisfeld, Ph.D., Steven D. Gillies, Ph.D., Susan L. Cohn, M.D., John M. Maris, M.D., and Paul M. Sondel, M.D., Ph.D., for the Children’s Oncology Group



Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte–macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma.


Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in combination with alternating GM-CSF and interleukin-2). Event-free survival and overall survival were compared between the immunotherapy group and the standard-therapy group, on an intention-to-treat basis.


A total of 226 eligible patients were randomly assigned to a treatment group. In the immunotherapy group, a total of 52% of patients had pain of grade 3, 4, or 5, and 23% and 25% of patients had capillary leak syndrome and hypersensitivity reactions, respectively. With 61% of the number of expected events observed, the study met the criteria for early stopping owing to efficacy. The median duration of follow-up was 2.1 years. Immunotherapy was superior to standard therapy with regard to rates of event-free survival (66±5% vs. 46±5% at 2 years, P = 0.01) and overall survival (86±4% vs. 75±5% at 2 years, P = 0.02 without adjustment for interim analyses).


Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma.

Neuroblastoma, a cancer of the sympathetic nervous system responsible for 12% of deaths associated with cancer in children under 15 years of age,1 is a heterogeneous disease, with nearly 50% of patients having a high-risk phenotype characterized by widespread dissemination of the cancer and poor long-term survival, even if intensive multimodal treatments are used.2 The initial results of the last randomized, controlled trial showing a significant improvement in outcomes were published over a decade ago3,4 and established the standard therapy for high-risk neuroblastoma: myeloablative therapy with stem-cell rescue, followed by the treatment of minimal residual disease with isotretinoin. However, more than half the patients receiving standard therapy have a relapse and ultimately die from the tumor. Thus, once remission is achieved, the major obstacle to a cure is residual chemotherapy-refractory disease that eludes current methods of detection.

A promising approach to treating minimal residual disease is immunotherapy targeting a tumor-associated antigen, the disialoganglioside GD2, which is uniformly expressed by neuroblastomas, most melanomas, and some other tumors.5,6 In normal human tissues, GD2 expression is restricted to neurons, skin melanocytes, and peripheral sensory nerve fibers.7 The high expression of GD2 in neuroblastomas and its restricted distribution in normal tissues make anti-GD2 monoclonal antibodies potentially suitable for immunotherapy. A chimeric human–murine anti-GD2 monoclonal antibody8 called ch14.18 has shown activity against neuroblastoma in preclinical studies9 and early-phase clinical trials10,11; this activity could be enhanced when ch14.18 is used in combination with granulocyte–macrophage colony-stimulating factor (GM-CSF)12,13 or interleukin-21416 to augment antibody-dependent cell-mediated cytotoxicity. The feasibility of administering ch14.18 in combination with GM-CSF, interleukin-2, and isotretinoin during the early post-transplantation period has been shown in two sequential pilot phase 1 studies.17,18 These paved the way for our study, the Children’s Oncology Group (COG) ANBL0032 randomized phase 3 study, in which we tested whether adding immunotherapy (consisting of ch14.18 with GM-CSF and interleukin-2) to isotretinoin therapy, as compared with the use of isotretinoin alone, improves the survival of children with high-risk neuroblastoma that is in remission after myeloablative therapy and stem-cell rescue.



The National Cancer Institute (NCI) was the sponsor of the study and also provided the ch14.18 monoclonal antibody. Bayer provided the GM-CSF. Neither the NCI nor Bayer had a role in the study design or analysis. The academic authors designed the study, collected and interpreted the data, prepared the manuscript, made the decision to submit the manuscript for publication, and vouch for the completeness and accuracy of the reported data and analyses. All data were maintained by the COG Statistics and Data Center and were reviewed by the COG data and safety monitoring committee.

Patients were enrolled at COG institutions (listed in Table S1 in the Supplementary Appendix, available with the full text of this article at after approval by the local institutional review board and after the patients provided written informed consent or assent, when applicable. Randomized enrollment began on October 18, 2001, and ended on January 13, 2009. The study was performed in accordance with the study protocol.


Eligible patients had high-risk neuroblastoma, defined strictly by the COG2 and confirmed by means of review of clinical, pathological, and biologic features by the COG Neuroblastoma Biology Study Committee and local institutions, before study enrollment. Other eligibility requirements were an age at diagnosis of under 31 years; completion of induction therapy, autologous stem-cell transplantation, and radiotherapy; achievement of at least a partial response at the time of evaluation before autologous stem-cell transplantation; autologous stem-cell transplantation performed within 9 months after the initiation of induction therapy; enrollment between day 50 and day 100 after the final autologous stem-cell transplantation; absence of progressive disease; and adequate organ function and a life expectancy of at least 2 months. An additional eligibility criterion enforced early on in the study was the requirement for enrollment in the COG biology study (ANBL00B1).

Patients with biopsy-proven residual disease after autologous stem-cell transplantation were eligible for enrollment but not for randomization and were nonrandomly assigned to receive immunotherapy. They were excluded from the primary efficacy analysis. Previous data indicate that patients with residual disease have a poorer prognosis than those without residual disease.4


Standard Therapy

Patients in the standard-therapy group received isotretinoin given at a dose of 160 mg per square meter of body-surface area per day, divided into two daily doses, for 14 consecutive days within each of six consecutive 28-day cycles.


Patients received ch14.18 at a dose of 25 mg per square meter per day for 4 consecutive days during each of five consecutive 4-week cycles. During the last 2 weeks in each of the five cycles, they also received isotretinoin at a dose of 160 mg per square meter per day (see the immunotherapy schedule in Fig. S1A in the Supplementary Appendix); this dose of isotretinoin was also given by itself during a final sixth cycle. During cycles 1, 3, and 5, GM-CSF (Leukine, Berlex) was given daily at a dose of 250 μg per square meter per day for 14 days, starting 3 days before ch14.18 was started (Fig. S1B in the Supplementary Appendix). During cycles 2 and 4, interleukin-2 (Proleukin, Chiron) was given, by means of continuous infusion, for 4 days during week 1 at a dose of 3.0×106 IU per square meter per day, as well as for 4 days during week 2 at a dose of 4.5×106 IU per square meter per day, concurrent with ch14.18 (Fig. S1C in the Supplementary Appendix).


The primary analysis was an intention-to-treat comparison of event-free survival in the two treatment groups. The study was designed to enroll 386 randomly assigned patients, for a statistical power of 80% with a two-sided log-rank test at a level of 0.05 (or a one-sided test at a level of 0.025) to detect an absolute difference of 15 percentage points between the two groups in the 3-year estimate of event-free survival (50% in the standard-therapy group vs. 65% in the immunotherapy group). Sequential monitoring of the intention-to-treat population was performed, and early stopping was considered if a significant difference between the two groups was found19 (Fig. S2 in the Supplementary Appendix) or if the conditional power fell below 20%. The relative risk of an event was calculated for standard therapy as compared with immunotherapy on the basis of the 3-year estimate of event-free survival; under the alternative hypothesis, the relative risk is equal to 1.6. The Lan–DeMets19 upper (efficacy) boundary was calculated with the spending function alpha×time2, for a cumulative alpha level of 0.025. A total of 137 events was expected to be reported. A secondary analysis of overall survival in the intention-to-treat population, according to treatment group, was to be performed only if the two groups were found to differ significantly with regard to event-free survival.

For event-free survival, the time to an event was defined as the time from study enrollment (which occurred after transplantation) until the first occurrence of relapse, progressive disease, secondary cancer, or death or, if none of these events occurred, until the last contact with the patient. Overall survival was defined as the time from study enrollment until death or the last contact with the patient, if death did not occur during the study. Kaplan–Meier survival curves20 were generated. Point estimates are reported as the estimate ±SE.21

Randomization occurred at the time of enrollment and was stratified on the basis of factors thought to potentially affect the post-transplantation outcome: the response before autologous stem-cell transplantation, induction-therapy protocol, number of transplantations of autologous stem cells, and purged versus nonpurged stem-cell infusion. Patients with biopsy-proven persistent disease after autologous stem-cell transplantation and radiotherapy were nonrandomly assigned to the immunotherapy group and were excluded from the primary outcome analyses.

We tested the comparability of the two treatment groups in terms of their known prognostic factors and stratification factors at the time of study enrollment by using a chi-square test. P values of less than 0.05 were considered to indicate statistical significance.



Of the 252 patients enrolled (Fig. 1), 1 patient was ineligible (the patient did not enroll in the COG biology study), and 25 patients with biopsy-proven persistent disease after autologous stem-cell transplantation were nonrandomly assigned to immunotherapy.

Figure 1
Enrollment, Randomization, and Follow-up of the Study Patients

The remaining 226 patients were randomly assigned to receive immunotherapy (113 patients) or standard therapy (113 patients) and were included in the primary analysis. All 251 eligible patients were analyzed for toxic effects. The median duration of follow-up after randomization for patients who were alive and had not had a study event was 2.1 years (range, 4 days to 6.9 years; see the Supplementary Appendix for details). There were no significant differences between the two groups with respect to baseline characteristics (Table 1).

Table 1
Characteristics of the 226 Study Patients at Baseline, According to Treatment Group, and Results of Analyses According to Treatment Group and Characteristics.*


As of January 13, 2009, with 226 eligible patients enrolled and randomly assigned to a treatment group (of 386 anticipated) and 83 of the expected 137 events reported (61%), the COG data and safety monitoring committee determined that the study met the criteria for early stopping of the randomization, on the basis of the superiority of immunotherapy over standard therapy with regard to event-free survival (Fig. S2 in the Supplementary Appendix). The 2-year estimate for event-free survival was 66±5% in the immunotherapy group and 46±5% in the standard-therapy group (P = 0.01) (Fig. 2A). Immunotherapy was also superior to standard therapy with regard to the estimated rate of overall survival (86±4% vs. 75±5% at 2 years, P = 0.02 without adjustment for interim analyses) (Fig. 2B).

Figure 2
Kaplan–Meier Estimates of Survival among the 226 Study Patients Who Had Been Randomly Assigned, According to Treatment Group

The effect of immunotherapy on the subgroup of patients 1 year of age or older who had stage 4 disease, according to the International Neuroblastoma Staging System (INSS), at the time of diagnosis was also analyzed, since this subgroup accounts for the majority of high-risk cases (179 of 226 randomized patients). The rate of event-free survival was significantly greater in the immunotherapy group (63±6% at 2 years) than in the standard-therapy group (42±6% at 2 years, P = 0.02) (Fig. 2C). There was also a trend toward improved overall survival with immunotherapy (84±4% at 2 years) as compared with standard therapy (76±5% at 2 years, P = 0.10) (Fig. 2D).


Twenty-five patients were nonrandomly assigned to undergo the immunotherapy regimen because of biopsy-proven residual disease after autologous stem-cell transplantation. The 2-year estimates for event-free survival and overall survival were 36±10% (16 events) and 76±9% (10 deaths, all disease-related), respectively (Fig. S3 in the Supplementary Appendix). The median duration of follow-up among the patients who did not have an event was 3.6 years (range, 1.0 to 6.7). All 25 patients were over 18 months of age at diagnosis, and 23 had INSS stage 4 disease; 6 tumors showed MYCN amplification, 16 had unfavorable histologic features, and 12 were diploid (see Table S2 in the Supplementary Appendix). A total of 21 of the 25 patients had a partial response before autologous stem-cell transplantation; only 1 of the 25 had undergone two autologous stem-cell transplantations (rather than one).


Survival rates were compared between the two treatment groups on the basis of nine prognostic factors (Table 1). The event-free survival was worse in patients with disease of INSS stage 4 than in patients with disease of INSS stage 2, 3, or 4S (P = 0.003). Diploidy, representing normal tumor-cell DNA index, was predictive of worse overall survival than hyperdiploidy (P = 0.007). A complete or very good partial response, as compared with a partial response, before autologous stem-cell transplantation was predictive of improved event-free survival (P = 0.04) and overall survival (P=0.02). No other factors were significantly predictive of the outcome. Although randomization was not stratified according to INSS stage or tumor ploidy, the two treatment groups were balanced with respect to the number of patients with stage 4 disease (P = 0.93), diploid tumors (P = 0.33), and a complete or very good partial response before transplantation (P = 0.96) (Table 1); therefore, the treatment-group comparisons were not influenced by these factors.


The immunotherapy regimen was associated with important treatment-related clinical toxic effects. The effects of most interest reported in the immunotherapy group were pain, hypotension, capillary leak syndrome, and hypersensitivity reactions (Tables 2 and and3),3), with relatively few toxic effects in the standardtherapy group. Pain of grade 3 or 4 was observed in 52% of patients (during 25% of 598 cycles of immunotherapy). Pain reactions in the immunotherapy group were most frequent during cycle 1, occurring in 37% of patients, and decreasing to 14% during cycle 5 (P<0.001) (Table 3). The most common site of pain was the abdomen. The capillary leak syndrome was reported in a total of 23% of patients, during 8% of immunotherapy cycles. It occurred more frequently during cycles 2 and 4, which involved interleukin-2, with incidences of 11% and 13%, respectively, as compared with 3 to 7% during courses involving GM-CSF (cycles 1, 3, and 5) (P = 0.06). Grade 3 or 4 hypersensitivity reactions were reported in 25% of patients, during 15% of immunotherapy cycles. Hypersensitivity reactions were more frequent during the two cycles involving interleukin-2, with incidences of 26% and 25%, as compared with 5 to 12% during the three cycles involving GM-CSF (P = 0.001). Such reactions may be attributable to symptoms and signs that reflect both toxic effects of interleukin-2 and antibody-related hypersensitivity.

Table 2
Toxic Effects of Grade 3 or 4, According to Treatment Group.*
Table 3
Toxic Effects of Grade 3 or 4 in Patients Randomly or Nonrandomly Assigned to Receive Immunotherapy, According to Immunotherapy Cycle.*

Other toxic effects that were common during immunotherapy cycles included fever (in 39% of patients), hypokalemia (35%), hyponatremia (23%), liver dysfunction (abnormal alanine aminotransferase level, 23%), hypotension (18%), diarrhea (13%), urticaria (13%), and hypoxia (13%). Early in the study, two patients were inadvertently given an overdose of the scheduled interleukin-2 (i.e., a dose >20 times the scheduled dose) due to a medication error; one of these patients died of interleukin-2–related capillary leak and pulmonary edema. No other treatment-related deaths were reported. All other toxic effects were self-limited and resolved soon after the cessation of treatment and well before the beginning of the subsequent treatment.


This randomized clinical trial tested the use of an immunotherapy regimen administered after autologous stem-cell transplantation, in order to enhance antibody-dependent cell-mediated cytotoxicity to GD2-positive tumor cells. The results indicate that the inclusion of the immunotherapy resulted in significantly superior event-free and overall survival. The rate of event-free survival during this study was superior in the immunotherapy group as compared with the standardtherapy group (66% vs. 46% at 2 years). The rate of overall survival was also superior with immunotherapy (85% at 2 years). At the time of this report, the data for overall survival had not yet met the stringent statistical criteria for early stopping that the data for event-free survival did, and the results are extremely unlikely to differ from those showing a benefit in event-free survival, though this is admittedly not out of the realm of statistical possibility. Even so, the 2-year estimate of event-free survival of 66% indicates that a substantial proportion of the 113 patients in the immunotherapy group had events (1 died from an interleukin-2 overdose, and 32 had a relapse, 18 of whom died after the relapse). Regarding the patients who were still alive after relapse, previous studies indicate that children with recurrent or progressive disease are rarely cured.22

Not surprisingly, immunotherapy was more effective in patients with minimal, rather than substantial, residual disease: the outcome was superior among patients who had been randomly assigned to a treatment group than among those nonrandomly assigned to receive immunotherapy for residual disease. Thus, despite the significant improvement in the rates of event-free survival and overall survival with this immunotherapy regimen, there is need for further improvement in treatment.

Though the use of the ch14.18 monoclonal antibody in combination with cytokines is associated with important toxic effects, these effects differ in scope, type, and duration from the myelosuppressive, renal, and gastrointestinal toxic effects of chemotherapy regimens used during the induction and consolidation phases of treatment.10,11 The toxic effects seen with the immunotherapy regimen used in our study were expected and were primarily attributable to antibody binding to GD2 expressed on normal nerve cells,23,24 to cytokine-mediated capillary leak,25 or to hypersensitivity reactions associated with the ch14.18 antibody or cytokines. These toxic effects may also reflect the proposed mechanism of action of this combination: effector functions induced by the monoclonal antibody, including complement activation, and distinct pathways of antibody-dependent cell-mediated cytotoxicity mediated by natural killer cells,16 neutrophils26,27 and monocytes.28

The immunotherapy regimen tested in this study was based on several considerations and preclinical data. Antibody-dependent cell-mediated cytotoxicity is often depressed in patients with cancer,29 and antibody-dependent cell-mediated cytotoxicity modulated by various effector cells can be augmented by independent cytokines, namely GM-CSF and interleukin-2. These cytokines increase the number of granulocytes or macrophages and natural killer cells, respectively, and enhance their ch14.18-directed antibody-dependent cell-mediated cytotoxicity.13 The feasibility of combining anti-GD2 monoclonal antibodies with cytokines was shown in a Pediatric Oncology Group phase 2 trial of ch14.18 and GM-CSF12 and a Children’s Cancer Group phase 1 study of 14.G2a and interleukin-2.30 Another consideration was that greater clinical effects would be seen if immunotherapy was given in patients with minimal residual disease.31 This hypothesis is consistent with the relatively small number of complete or partial responses to anti-GD2 monoclonal antibodies (administered with or without cytokines) in children who have a relapse of neuroblastoma and adults who have melanoma with bulky disease.1012,14

In patients with newly diagnosed high-risk neuroblastoma, we chose to achieve minimal residual disease through the use of conventional induction therapy and intensive consolidation therapy with autologous stem-cell transplantation. Providing anti-GD2 antibody with cytokines after autologous stem-cell transplantation may also promote immune-cell activation and elimination of immunosuppression, a concept being tested in separate ongoing studies of cell-mediated cancer immunotherapy.32 Our two small, sequential pilot phase 1 studies of ch14.18 in combination with GM-CSF or with GM-CSF and interleukin-217,18 showed the feasibility of giving ch14.18 with these cytokines during the early post-transplantation period. The second of these studies showed a 3-year estimate of overall survival of 78%, reflecting a benefit in a comparison with historical controls,17 a benefit now confirmed in the current randomized trial.

In a separate, nonrandomized study, Simon and colleagues performed a retrospective analysis involving 334 children with high-risk neuroblastoma.33 All the children had completed initial induction therapy (with or without autologous stem-cell transplantation), and 166 received ch14.18 at doses similar to the dose used in the current study. In contrast to our results, there was no significant improvement in the rate of event-free survival or overall survival among children receiving ch14.18 as compared with those not receiving the antibody, although an updated analysis with a median follow-up period of 10.3 years (range, 2.3 to 17.7) indicated that ch14.18 may prevent late relapse.34 Although our study differs from the study by Simon and colleagues with respect to the dosing schedule (six cycles of immunotherapy, with cycles every other month, vs. five cycles, with cycles every month) and the timing of the start immunotherapy (within 100 days after autologous stem-cell transplantation vs. a range of 39.5 to 343 days [median, 65.5 days]), the primary difference may be that our study included treatment with GM-CSF and interleukin-2 to activate antibody-dependent cell-mediated cytotoxicity and treatment with isotretinoin. The difference in outcome between the study by Simon and coworkers and our study therefore suggests, though does not prove, that the addition of GM-CSF and interleukin-2 augments the antibody-dependent cell-mediated cytotoxicity in vivo conferred by the ch14.18 monoclonal antibody and improves survival. Although we cannot entirely rule out the possibility that the observed therapeutic benefit was due to the cytokines alone, clinical studies showing the efficacy of interleukin-2 or GM-CSF monotherapy in patients with neuroblastoma are lacking.

Other tumor-reactive monoclonal antibodies being used or tested as cancer treatment can induce antibody-dependent cell-mediated cytotoxicity; these include rituximab, trastuzumab, and cetuximab.3537 To date, published clinical trials of regimens in which interleukin-2 or GM-CSF was added to these other monoclonal antibodies have not shown any benefit over treatment with the monoclonal antibody alone.38,39 However, these published studies have focused on treatment for refractory or relapsed disease. The results from our study suggest that the efficacy of ch14.18 used in combination with GM-CSF and interleukin-2 may be detected more readily when tested as adjuvant therapy or in patients with minimal residual disease. Our findings also suggest that protocol designs similar to that used in the COG study may be appropriate for testing of other monoclonal antibodies that mediate antibody-dependent cell-mediated cytotoxicity.

In summary, the addition of ch14.18, GM-CSF, and interleukin-2 to isotretinoin therapy was associated with improved event-free and overall survival among children with high-risk neuroblastoma who had a response to initial chemotherapy and received immunotherapy within 100 days after autologous stem-cell transplantation. Our data suggest that more routine use of this immunotherapy regimen for such patients may be beneficial. Future avenues of investigation include developing more effective and less toxic ways to stimulate ch14.18-mediated antibody-dependent cell-mediated cytotoxicity and identifying more efficacious GD2-targeted monoclonal antibodies40 or genetically modified constructs targeting GD2.

Supplementary Material



Supported by grants from the National Institutes of Health (U10-CA98543, U10-CA98413, and U10-CA29139) and the Food and Drug Administration (FD-R-002319).

We thank Drs. Steve Creekmore, Toby Hecht, and Karen Muszynski and members of the Biopharmaceutical Development Program of the National Cancer Institute at Frederick for producing ch14.18 for this clinical trial; Bayer for providing the GM-CSF; and Dina Wills, James Bradley, Andrea Williams, Meera Raman, Betsy Bickert Poon, Pharm.D., and John Wiernikowski, Pharm.D., for providing technical and pharmaceutical assistance.

Funded by the National Institutes of Health and the Food and Drug Administration;

Footnotes number, NCT00026312.

Disclosure forms provided by the authors are available with the full text of this article at

Presented in part at the 45th annual meeting of the American Society of Clinical Oncology, Orlando, FL, May 29–June 2, 2009.


1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER[large star]Stat mortality database: total US. Bethesda, MD: National Cancer Institute; 1969–2006.
2. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106–20. [PubMed]
3. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999;341:1165–73. [PubMed]
4. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children’s Oncology Group study. J Clin Oncol. 2009;27:1007–13. [PMC free article] [PubMed]
5. Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984;44:5914–20. [PubMed]
6. Cheung NK, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987;5:1430–40. [PubMed]
7. Svennerholm L, Bostrom K, Fredman P, et al. Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta. 1994;1214:115–23. [PubMed]
8. Gillies SD, Lo KM, Wesolowski J. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods. 1989;125:191–202. [PubMed]
9. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol. 1990;144:1382–6. [PubMed]
10. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol. 1998;16:2169–80. [PubMed]
11. Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer. 1995;31A:261–7. [PubMed]
12. Yu AL, Batova A, Alvarado C, Rao VJ, Castleberry RP. Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma. Proc Am Soc Oncol. 1997;6:1846.
13. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res. 1991;51:144–9. [PubMed]
14. Albertini MR, Hank JA, Schiller JH, et al. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res. 1997;3:1277–88. [PubMed]
15. Kendra K, Malkovska V, Allen M, Guzman J, Albertini M. In vivo binding and antitumor activity of Ch14.18. J Immunother. 1999;22:423–30. [PubMed]
16. Hank JA, Robinson RR, Surfus J, et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res. 1990;50:5234–9. [PubMed]
17. Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children’s Oncology Group. J Clin Oncol. 2009;27:85–91. [PMC free article] [PubMed]
18. Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children’s Cancer Group Study. J Clin Oncol. 2000;18:4077–85. [PubMed]
19. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659–63.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
21. Greenwood M. The natural duration of cancer. Rep Public Health Med Subj (Lond) 1926;33:1–26.
22. Garaventa A, Parodi S, De Bernardi B, et al. Outcome of children with neuroblastoma after progression or relapse: a retrospective study of the Italian Neuroblastoma Registry. Eur J Cancer. 2009;45:2835–42. [PubMed]
23. Slart R, Yu AL, Yaksh TL, Sorkin LS. An animal model of pain produced by systemic administration of an immunotherapeutic anti-ganglioside antibody. Pain. 1997;69:119–25. [PubMed]
24. Xiao WH, Yu AL, Sorkin LS. Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody. Pain. 1997;69:145–51. [PubMed]
25. Dutcher J, Atkins MB, Margolin K, et al. Kidney cancer: the Cytokine Working Group experience (1986–2001): part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol. 2001;18:209–19. [PubMed]
26. Kushner BH, Cheung NK. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blood. 1992;79:1484–90. [PubMed]
27. Barker E, Reisfeld RA. A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. Cancer Res. 1993;53:362–7. [PubMed]
28. Leidi M, Gotti E, Bologna L, et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol. 2009;182:4415–22. [PubMed]
29. Dallegri F, Ballestrero A, Ottonello L, Patrone F. Defective antibody-dependent tumour cell lysis by neutrophils from cancer patients. Clin Exp Immunol. 1989;77:58–61. [PubMed]
30. Frost JD, Hank JA, Reaman GH, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14. G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children’s Cancer Group. Cancer. 1997;80:317–33. [PubMed]
31. Neal ZC, Yang JC, Rakhmilevich AL, et al. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res. 2004;10:4839–47. [PubMed]
32. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21:233–40. [PMC free article] [PubMed]
33. Simon T, Hero B, Faldum A, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol. 2004;22:3549–57. [PubMed]
34. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Berthold F. No success of anti-GD2 treatment in high risk neuroblastoma? A critical appraisal. Pediatr Blood Cancer. 2009;53:708. abstract.
35. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940–7. [PubMed]
36. Musolino A, Naldi N, Bortesi B, et al. Immunoglobin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26:1789–96. [PubMed]
37. Taylor RJ, Chan SL, Wood A, et al. Fc-gRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 2009;58:997–1006. [PubMed]
38. Khan KD, Emmanouilides C, Benson DM, Jr, et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin’s lymphoma. Clin Cancer Res. 2006;12:7046–53. [PubMed]
39. Mani A, Roda J, Young D, et al. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat. 2009;117:83–9. [PMC free article] [PubMed]
40. Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children’s Oncology Group. Clin Cancer Res. 2006;12:1750–9. [PMC free article] [PubMed]